Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

3.699 -0.011 (-0.29%)
Streaming Delayed Price Updated: 10:34 AM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.